| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 910 | 2022 |
| Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes JO Morales, KR Fathe, A Brunaugh, S Ferrati, S Li, M Montenegro-Nicolini, ... The AAPS journal 19, 652-668, 2017 | 143 | 2017 |
| Formulation techniques for high dose dry powders AD Brunaugh, HDC Smyth International journal of pharmaceutics 547 (1-2), 489-498, 2018 | 57 | 2018 |
| Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth PloS one 16 (2), e0246803, 2021 | 51 | 2021 |
| Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization AD Brunaugh, SU Jan, S Ferrati, HDC Smyth Molecular pharmaceutics 14 (11), 4019-4031, 2017 | 45 | 2017 |
| Effect of particle formation process on characteristics and aerosol performance of respirable protein powders AD Brunaugh, T Wu, SR Kanapuram, HDC Smyth Molecular pharmaceutics 16 (10), 4165-4180, 2019 | 40 | 2019 |
| Influence of formulation factors on the aerosol performance and stability of lysozyme powders: a systematic approach S Ferrati, T Wu, O Fuentes, AD Brunaugh, SR Kanapuram, HDC Smyth AAPS PharmSciTech 19, 2755-2766, 2018 | 26 | 2018 |
| Process optimization and particle engineering of micronized drug powders via milling A Brunaugh, HDC Smyth Drug Delivery and Translational Research 8, 1740-1750, 2018 | 24 | 2018 |
| Essential pharmaceutics AD Brunaugh, HDC Smyth, RO Williams III Springer, 2019 | 19 | 2019 |
| Broad-spectrum, patient-adaptable inhaled niclosamide-lysozyme particles are efficacious against coronaviruses in lethal murine infection models AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth BioRxiv, 2020.09. 24.310490, 2020 | 18 | 2020 |
| Inhaled fixed-dose combination powders for the treatment of respiratory infections AD Brunaugh, S Sharma, H Smyth Expert opinion on drug delivery 18 (8), 1101-1115, 2021 | 17 | 2021 |
| Connexin membrane materials as potent inhibitors of breast cancer cell migration S Ferrati, AK Gadok, AD Brunaugh, C Zhao, LA Heersema, HDC Smyth, ... Journal of The Royal Society Interface 14 (133), 20170313, 2017 | 16 | 2017 |
| A quality by design framework for capsule-based dry powder inhalers L Ding, AD Brunaugh, S Stegemann, SV Jermain, MJ Herpin, J Kalafat, ... Pharmaceutics 13 (8), 1213, 2021 | 15 | 2021 |
| Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder AD Brunaugh, L Ding, T Wu, M Schneider, R Khalaf, HDC Smyth Journal of Pharmaceutical Sciences 111 (2), 403-416, 2022 | 11 | 2022 |
| Pulmonary drug delivery AD Brunaugh, HDC Smyth, RO Williams III, AD Brunaugh, HDC Smyth, ... Essential Pharmaceutics, 163-181, 2019 | 6 | 2019 |
| Overview of the delivery technologies for inhalation aerosols DF Moraga-Espinoza, AD Brunaugh, S Ferrati, LA Heersema, MJ Herpin, ... Inhalation Aerosols, 123-143, 2019 | 5 | 2019 |
| Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB/c mice with chronic Mycobacterium tuberculosis infection AD Brunaugh, A Walz, Z Warnken, C Pearce, J Munoz Gutierrez, ... Antimicrobial Agents and Chemotherapy 66 (9), e00186-22, 2022 | 4 | 2022 |
| Topical and transdermal drug delivery AD Brunaugh, HDC Smyth, RO Williams III, AD Brunaugh, HDC Smyth, ... Essential Pharmaceutics, 131-147, 2019 | 4 | 2019 |
| Nasal drug delivery AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential Pharmaceutics, 215-220, 2024 | 3 | 2024 |
| Modified release solid oral dosage forms AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential pharmaceutics, 73-89, 2024 | 3 | 2024 |
